Prrx2-KO Mouse
Common Name
Prrx2-KO
제품 ID
S-KO-04182
Backgroud
C57BL/6NCya
품종 계통계통 ID
KOCMP-20204-Prrx2-B6N-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Prrx2-KO Mouse (카탈로그 번호 S-KO-04182)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Prrx2-KO
품종 계통계통 ID
KOCMP-20204-Prrx2-B6N-VA
유전자명
제품 ID
S-KO-04182
유전자 별칭
S8, Prx2
배경
C57BL/6NCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 2
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000041659
NCBI 전사체 ID
NM_009116
타겟 영역
Exon 2~3
유효 영역 크기
~1.3 kb
유전자 연구 개요
PRRX2, the paired-related homeobox transcription factor, is involved in multiple biological processes and disease-related pathways. It can participate in regulating gene transcription, and is associated with pathways like Wnt/β-catenin, Hippo, and is related to ferroptosis, cell proliferation, apoptosis, invasion, and migration. Genetic models can be used to study its functions in different biological contexts [1-10].
In glioblastoma, circLRFN5 binds to PRRX2 protein, promoting its degradation via a ubiquitin-mediated proteasomal pathway. PRRX2 can transcriptionally upregulate GCH1 expression, which is a ferroptosis suppressor [1]. In osteoporosis, myoblast-derived exosomal Prrx2 enhances osteogenic differentiation of BMSCs by transcriptionally regulating lncRNA-MIR22HG to activate the Hippo pathway [2]. In prostate cancer, activation of PRRX2 promotes enzalutamide resistance, and it is related to alterations in the CDK4/6/Rb/E2F and BCL2 pathways [3]. In lung adenocarcinoma, PRRX2 is highly expressed, acts as a positive regulator of cell proliferation and a negative regulator of apoptosis, and can bind with the PSMD1 promoter to regulate its expression [4]. In skin cells, silencing Marveld3 upregulates PRRX2, which may attenuate radiation-induced lipid peroxidation [5]. In colon cancer, inhibition of PRRX2 reduces invasive and migrating abilities, hinders epithelial-mesenchymal transition (EMT), and suppresses liver metastasis through inactivation of the Wnt/β-catenin pathway [6]. In breast cancer, silencing Prrx2 expression inhibits cell proliferation and tumor growth, and down-regulates the activity of the Wnt/β-catenin signaling pathway [7]. Overexpression of PRRX2 in mammary epithelial cells enhances invasion, migration, and induces partial EMT [8]. In tooth development, Prrx2 may regulate Panx3 expression during odontoblastic differentiation [9].
In conclusion, PRRX2 plays crucial roles in various biological processes and disease conditions. Through gene-based research models, we've learned that it impacts processes like ferroptosis, osteogenic differentiation, cancer cell behaviors (such as proliferation, invasion, and drug resistance), and tooth development. These findings provide insights into disease mechanisms and potential therapeutic targets related to Prrx2-associated pathways.
References:
1. Jiang, Yang, Zhao, Junshuang, Li, Rongqing, Gao, Liang, Cui, Daming. 2022. CircLRFN5 inhibits the progression of glioblastoma via PRRX2/GCH1 mediated ferroptosis. In Journal of experimental & clinical cancer research : CR, 41, 307. doi:10.1186/s13046-022-02518-8. https://pubmed.ncbi.nlm.nih.gov/36266731/
2. Li, Yunchao, Wang, Xiaoxiao, Pan, Changyu, Chen, Zejun, He, Haoyu. 2023. Myoblast-derived exosomal Prrx2 attenuates osteoporosis via transcriptional regulation of lncRNA-MIR22HG to activate Hippo pathway. In Molecular medicine (Cambridge, Mass.), 29, 54. doi:10.1186/s10020-023-00649-y. https://pubmed.ncbi.nlm.nih.gov/37081396/
3. Rodríguez, Yara, Unno, Kenji, Truica, Mihai I, Han, Huiying, Abdulkadir, Sarki A. . A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. In Cancer research, 82, 2110-2123. doi:10.1158/0008-5472.CAN-21-3565. https://pubmed.ncbi.nlm.nih.gov/35405009/
4. Liu, Lihua, Liu, Aihua, Liu, Xuezheng. 2022. PRRX2 predicts poor survival prognosis, and promotes malignant phenotype of lung adenocarcinoma via transcriptional activates PSMD1. In Translational oncology, 27, 101586. doi:10.1016/j.tranon.2022.101586. https://pubmed.ncbi.nlm.nih.gov/36379103/
5. Cao, Jinming, Wu, Mengyao, Mo, Wei, Zhang, Bin, Cao, Jianping. 2024. Upregulation of PRRX2 by silencing Marveld3 as a protective mechanism against radiation-induced ferroptosis in skin cells. In Molecular medicine (Cambridge, Mass.), 30, 182. doi:10.1186/s10020-024-00958-w. https://pubmed.ncbi.nlm.nih.gov/39434056/
6. Chai, Wen-Xiao, Sun, Li-Guo, Dai, Fu-Hong, Zheng, Ning-Gang, Cai, Hong-Yi. 2019. Inhibition of PRRX2 suppressed colon cancer liver metastasis via inactivation of Wnt/β-catenin signaling pathway. In Pathology, research and practice, 215, 152593. doi:10.1016/j.prp.2019.152593. https://pubmed.ncbi.nlm.nih.gov/31471104/
7. Lü, Z D, Yang, Z C, Jin, L Y, Kong, B, Wang, H B. . [Effects of Prrx2 gene silencing on the proliferation of breast cancer and its molecular mechanisms]. In Zhonghua yi xue za zhi, 100, 942-946. doi:10.3760/cma.j.cn112137-20190710-01309. https://pubmed.ncbi.nlm.nih.gov/32234171/
8. Juang, Yu-Lin, Jeng, Yung-Ming, Chen, Chi-Long, Lien, Huang-Chun. 2016. PRRX2 as a novel TGF-β-induced factor enhances invasion and migration in mammary epithelial cell and correlates with poor prognosis in breast cancer. In Molecular carcinogenesis, 55, 2247-2259. doi:10.1002/mc.22465. https://pubmed.ncbi.nlm.nih.gov/26824226/
9. Tanaka, Manami, Sugimoto, Asuna, Iwata, Kokoro, Oishi, Atsushi, Iwamoto, Tsutomu. 2024. Prrx2, the paired-related homeobox transcription factor, functions as a potential regulator of pannexin 3 expression in odontoblast differentiation. In Journal of oral biosciences, 67, 100601. doi:10.1016/j.job.2024.100601. https://pubmed.ncbi.nlm.nih.gov/39733924/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
